The Journey of Imatinib

Imatinib is a 2-phenylaminopyrimidine tyrosine kinase inhibitor
with oral bioavailability of approximately 98% — one of the highest of any oncology drug. Peak
plasma concentrations are achieved within 2-4 hours after oral dosing. Food has a minimal effect
on overall absorption; the drug may be taken with or without food, though taking with a large meal
and water is recommended to reduce GI irritation. The drug is available as 100 mg and 400 mg tablets
and also as a capsule that can be dispersed in water or apple juice for patients unable to swallow
tablets. At standard CML dosing (400 mg/day for chronic phase), steady-state concentrations are
achieved within approximately 7 days. There is no saturable absorption mechanism — bioavailability
remains essentially complete across the dose range. Imatinib is also used in GIST (gastrointestinal
stromal tumors), Ph+ ALL, and other indications at doses of 400-800 mg/day.

Imatinib distributes extensively with a volume of distribution
of approximately 435 L, suggesting substantial sequestration in tissues well beyond the vascular
compartment. Plasma protein binding is approximately 95%, primarily to alpha-1-acid glycoprotein
(AGP, AAG) and albumin. The binding to AGP is particularly important: AGP is an acute-phase protein
that increases with inflammation and cancer, and high AGP levels can reduce the free fraction of
imatinib — an effect proposed to contribute to some cases of pharmacokinetic resistance. Imatinib
distributes well into tumor tissue including BCR-ABL-expressing leukemic cells. CNS penetration
is limited (CSF concentrations approximately 0.2-2% of plasma), which explains the incomplete
efficacy against CNS CML or isolated CNS relapse, and is the rationale for exploring CNS-penetrant
second-generation TKIs (asciminib) in this context.

The BCR-ABL oncoproteins are constitutively active tyrosine kinases
generated by the t(9;22)(q34;q11) Philadelphia chromosome translocation, fusing the BCR gene on
chromosome 22 with the ABL1 tyrosine kinase gene on chromosome 9. The resulting fusion proteins
(p210 BCR-ABL in CML; p190 in Ph+ ALL) constitutively activate tyrosine kinase activity,
phosphorylating substrates (RAS/MAPK, PI3K/AKT, STAT5) that drive uncontrolled proliferation,
resistance to apoptosis, and enhanced survival of hematopoietic progenitors. Imatinib binds the
ATP-binding pocket of ABL1 in its inactive (DFG-out) conformation — a conformation specific to
kinases with a regulatory loop in the inactive position. This binding prevents ATP entry, blocking
phosphoryl transfer and abolishing kinase activity. The same binding pocket conformation allows
imatinib to also inhibit c-KIT (PDGFRA/PDGFRB family) — the basis for imatinib efficacy in
GIST (KIT-mutant) and hypereosinophilic syndrome (FIP1L1-PDGFRA).

Imatinib is primarily metabolized by CYP3A4 (major) and CYP1A2,
CYP2D6, CYP2C9, CYP2C19 (minor contributors) to N-desmethyl-imatinib (CGP74588), an active
metabolite with approximately equal in vitro potency against BCR-ABL. CGP74588 constitutes
approximately 10-15% of total drug-related AUC. Additional inactive metabolites undergo further
oxidation and glucuronidation. Imatinib is a moderate inhibitor of CYP3A4 and a potent inhibitor
of CYP2D6 (relevant for co-administered drugs), as well as a substrate and inhibitor of P-gp and
BCRP efflux transporters. CYP3A4 inducers (rifampicin, carbamazepine, St. John's Wort) reduce
imatinib AUC by 60-75%, potentially leading to loss of response. CYP3A4 inhibitors (ketoconazole,
clarithromycin) substantially increase imatinib exposure. Food has minimal impact on metabolism.

Imatinib and its metabolites are excreted predominantly in feces
(approximately 68%) via biliary excretion, with approximately 13% in urine. Only ~5% is excreted
as unchanged drug in feces and urine. Elimination half-life of imatinib is approximately 18 hours
and of N-desmethyl-imatinib approximately 40 hours, enabling once-daily dosing. Steady-state
is achieved within 7 days with once-daily dosing (400 mg). Renal impairment does not significantly
alter imatinib pharmacokinetics; however, patients with renal impairment often have higher AGP
levels, potentially altering free fraction. No dose adjustment is required for mild-moderate hepatic
impairment, but dose reduction is recommended for severe hepatic impairment. Plasma trough
concentrations >1,000 ng/mL are associated with superior molecular response, supporting the role
of TDM in optimizing imatinib therapy.

Imatinib (Gleevec/Glivec) transformed CML from a disease with a
median survival of 3-5 years to one where the majority of patients achieve survival equivalent to
age-matched controls. The IRIS trial (2003) showed 89% complete cytogenetic response at 18 months.
Resistance mechanisms include kinase domain point mutations (most importantly T315I — the gatekeeper
mutation resistant to all first and second-generation TKIs, only overcome by ponatinib and asciminib),
BCR-ABL amplification, and non-BCR-ABL mechanisms (overexpression of drug efflux pumps, reduced
influx via OCT1). Adverse effects include edema (periorbital, ankle), myalgia, nausea, and
bone marrow suppression. The precedent imatinib set for molecularly targeted therapy fundamentally
changed oncology drug development strategy.